An interventional study of Substance-specific inhibition training and Control training in Alcohol Use Disorder (AUD), Cocaine Use Disorder (CUD) and Substance Use Disorder (SUD), sponsored by University of Bern. Completed at 1 site in Switzerland. Open to participants aged 14 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Bern · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Alcoholism with a site in Switzerland — 4 open to participants now, 4 under way, none of them phase 3. Alcoholism · Switzerland.
Among the 12 studies in Alcoholism with a site in Switzerland, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, and was the 12th registered.
1,678 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →4 of the 12 studies in Alcoholism with a site in Switzerland are open now. Recruiting first, the newest first:
Felix Mueller · Sites in Switzerland
Ages 25+
Dr. med. Marcus Herdener · Sites in Switzerland
Ages 18–65
University of Bern · Sites in Switzerland
Ages 18–80
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–80
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 14 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 57 across the 10 interventional studies, 188 across the 2 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 7 most frequent:
University of Bern is the lead sponsor of 209 studies on the registry; 46 are open to participants now.
University of Bern has 5 studies filed under Alcoholism — fewer than ten, so there is no comparison to draw.
2 of the studies in Alcoholism with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06969937Dr. med. Marcus HerdenerKetamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder | 2026-12 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Alcoholism with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Substance misuse is one of the most common risk factors for health problems and premature death among adolescents and young adults worldwide. Although there are effective treatments for substance use disorder (SUD), there is still a need to further improve their effectiveness and make them easier to access. Early research suggests that substance-specific inhibition training, when used in addition to specialized treatment, can improve treatment outcomes. This training aims to strengthen inhibition specifically in situations with substance-related cues. The goal of this project is to offer this training for the first time in the form of a smartphone app, which is expected to increase the availability of the training. The main aim of the study is to evaluate whether this new app-based cognitive training is feasible as an add-on to the treatment of SUD in adolescents and young adults. In addition, the study will gather preliminary insights into whether the training affects drinking behavior and related brain processes. The project will be conducted as a double-blind, clinical pilot study. A total of 210 adolescents and young adults between 14 and 35 years old will be recruited from five specialized treatment centers. After the first study visit, participants will be randomly assigned to one of two groups: (1) an intervention group receiving the alcohol-specific inhibition training or (2) a control group receiving a similar alcohol-nonspecific inhibition training. During their participation, all participants will complete six short training sessions with the app. About one month later, they will complete six additional booster training sessions. This research may help develop effective, easily accessible tools to support young people with substance use disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional exclusion criteria for Electroencephalography (EEG)-substudy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
12 sessions of substance-specific inhibition training
Other: Substance-specific inhibition training
12 sessions of unspecific inhibition training
Other: Control training
Twelve sessions of substance-specific inhibition training
Twelve sessions of unspecific inhibition training
Number of participants recruited
Number of participants recruited during the recruitment period in all participating clinical centers is one indicator of the feasibility of implementing substance-specific inhibition training in a smartphone app.
Time frame: From enrollment to the last assessment, approx. 16 weeks
Number of participants successfully completing the program
Number of participants successfully completing the program is one indicator of the feasibility of implementing substance-specific inhibition training in a smartphone app.
Time frame: At the last assessment, approx. 16 weeks from enrollment
Proportion of participants completing the follow-up visits
Proportion of participants completing the follow-up visits is another indicator of feasibility.
Time frame: At the last assessment, approx. 16 weeks from enrolment
Number of participants adhering to the treatment
Number of participants adhering to the treatment, i.e. participating in all planned twelve training sessions, is another indicator of feasibility of implementing substance-specific inhibition training in a smartphone app.
Time frame: From enrollment to last last training session, approx. 10 weeks
Number of adverse events
Number of adverse events is another indicator of feasibility of implementing substance-specific inhibition training in a smartphone app.
Time frame: From enrollment to the last assessment, approx. 16 weeks
Percentage of days abstinent
Percentage of days abstinent is the main secondary outcome indicating preliminary effects on consumption behavior. It is measured by the Timeline Follow-Back method at 3-month follow-up.
Time frame: At the last assessment, approx. 16 weeks from enrolment
Number of heavy drinking days
Number of heavy drinking days is another secondary outcome indicating preliminary effects on drinking behavior. It is measured by the Timeline Follow-Back method at 3-month follow-up.
Time frame: At the last assessment, approx. 16 weeks from enrolment
P3-component of event-related potentials
The P3-component of event-related potentials measured with electroencephalography (EEG) is used as a secondary outcome in the EEG- substudy to investigate whether substance-specific inhibition training modifies the neurophysiology of substance-specific inhibition
Time frame: 4-6 weeks.
N2-component of event-related potentials
The N2-component of event-related potentials measured with electroencephalography (EEG) is used as a secondary outcome in the EEG- substudy to investigate whether substance-specific inhibition training modifies the neurophysiology of substance-specific inhibition
Time frame: 4-6 weeks.
Plan to share: No — The decision to share IPD depends on the explicit consent provided by participants as part of the informed consent process. Since it is not possible to determine in advance whether participants will grant permission for data sharing, IPD sharing is not planned.
Ran from Jul 2025 to primary completion in Oct 2026, 14 months.
Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's 14 months is below that.
Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.